Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Approach to the patient with hyperpigmentation disorders

Neelam Vashi, MD
Roopal Kundu, MD
Section Editor
Erik Stratman, MD
Deputy Editor
Rosamaria Corona, MD, DSc


Hyperpigmentation is the darkening or increase in the natural color of the skin usually due to an increased deposition of melanin (hypermelanosis) in the epidermis and/or dermis. Less frequently, it may be caused by the deposition in the dermis of endogenous or exogenous pigments, such as hemosiderin, iron, or heavy metals.

Hyperpigmentation is a feature of a multitude of clinical conditions, ranging from normal variations of skin color to acquired and inherited syndromes, and is one of the most common reasons for dermatologic consultation, particularly in patients with darker skin types [1-3]. Although hyperpigmentation is not harmful, it can cause significant cosmetic disfigurement and become a persistent psychosocial burden for the patient, due to the limited efficacy of the available treatments.

This topic will review the approach to the patient with hyperpigmentation disorders. Melasma and postinflammatory hyperpigmentation are discussed separately. Benign and malignant melanocytic tumors are also discussed separately.

(See "Melasma".)

(See "Postinflammatory hyperpigmentation".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: Sep 26, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ (Eds), McGraw-Hill Medical, 2012. Vol 1, p.804.
  2. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis 2007; 80:387.
  3. Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol 2014; 13:401.
  4. Ito S, Wakamatsu K. Chemistry of Melanins. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, Malden, MA 2006. p.282.
  5. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46:S41.
  6. Szabó G, Gerald AB, Pathak MA, Fitzpatrick TB. Racial differences in the fate of melanosomes in human epidermis. Nature 1969; 222:1081.
  7. Ranu H, Thng S, Goh BK, et al. Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification. Dermatol Surg 2011; 37:1297.
  8. Speeckaert R, Van Gele M, Speeckaert MM, et al. The biology of hyperpigmentation syndromes. Pigment Cell Melanoma Res 2014; 27:512.
  9. Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, New York 2012. Vol 1.
  10. Ortonne JP, Nordlund JJ. Mechanisms that cause abnormal skin color. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, Malden, MA 2006. p.521.
  11. Chuh AA, Wong WC, Wong SY, Lee A. Procedures in primary care dermatology. Aust Fam Physician 2005; 34:347.
  12. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005; 27:96.
  13. Gilchrest BA, Fitzpatrick TB, Anderson RR, Parrish JA. Localization of malanin pigmentation in the skin with Wood's lamp. Br J Dermatol 1977; 96:245.
  14. Kang HY, Bahadoran P, Suzuki I, et al. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Exp Dermatol 2010; 19:e228.
  15. Calzavara-Pinton P, Longo C, Venturini M, et al. Reflectance confocal microscopy for in vivo skin imaging. Photochem Photobiol 2008; 84:1421.
  16. Hofmann-Wellenhof R, Wurm EM, Ahlgrimm-Siess V, et al. Reflectance confocal microscopy--state-of-art and research overview. Semin Cutan Med Surg 2009; 28:172.
  17. Kang HY, Bahadoran P, Ortonne JP. Reflectance confocal microscopy for pigmentary disorders. Exp Dermatol 2010; 19:233.
  18. Ardigo M, Cameli N, Berardesca E, Gonzalez S. Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy: a preliminary study. J Eur Acad Dermatol Venereol 2010; 24:1296.
  19. Yamaguchi K, Watanabe C, Kawaguchi A, et al. Association of melanocortin 1 receptor gene (MC1R) polymorphisms with skin reflectance and freckles in Japanese. J Hum Genet 2012; 57:700.
  20. Bastiaens M, ter Huurne J, Gruis N, et al. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 2001; 10:1701.
  21. Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:367.
  22. Polder KD, Landau JM, Vergilis-Kalner IJ, et al. Laser eradication of pigmented lesions: a review. Dermatol Surg 2011; 37:572.
  23. Veraitch O, Rickaby W, Robson A, et al. Early-onset dermatosis papulosa nigra. Br J Dermatol 2016; 174:1148.
  24. Babapour R, Leach J, Levy H. Dermatosis papulosa nigra in a young child. Pediatr Dermatol 1993; 10:356.
  25. Hafner C, Landthaler M, Mentzel T, Vogt T. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra. Br J Dermatol 2010; 162:508.
  26. Lupo MP. Dermatosis papulosis nigra: treatment options. J Drugs Dermatol 2007; 6:29.
  27. Garcia MS, Azari R, Eisen DB. Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatol Surg 2010; 36:1968.
  28. Kundu RV, Joshi SS, Suh KY, et al. Comparison of electrodesiccation and potassium-titanyl-phosphate laser for treatment of dermatosis papulosa nigra. Dermatol Surg 2009; 35:1079.
  29. Ali FR, Bakkour W, Ferguson JE, Madan V. Carbon dioxide laser ablation of dermatosis papulosa nigra: high satisfaction and few complications in patients with pigmented skin. Lasers Med Sci 2016; 31:593.
  30. Bruscino N, Conti R, Campolmi P, et al. Dermatosis Papulosa Nigra and 10,600-nm CO2 laser, a good choice. J Cosmet Laser Ther 2014; 16:114.
  31. Katz TM, Goldberg LH, Friedman PM. Dermatosis papulosa nigra treatment with fractional photothermolysis. Dermatol Surg 2009; 35:1840.
  32. Nayak RS, Kotrashetti VS, Hosmani JV. Laugier-Hunziker syndrome. J Oral Maxillofac Pathol 2012; 16:245.
  33. Sheridan AT, Dawber RP. Laugier-Hunziker syndrome: treatment with cryosurgery. J Eur Acad Dermatol Venereol 1999; 13:146.
  34. Zuo YG, Ma DL, Jin HZ, et al. Treatment of Laugier-Hunziker syndrome with the Q-switched alexandrite laser in 22 Chinese patients. Arch Dermatol Res 2010; 302:125.
  35. Ferreira MJ, Ferreira AM, Soares AP, Rodrigues JC. Laugier-Hunziker syndrome: case report and treatment with the Q-switched Nd-Yag laser. J Eur Acad Dermatol Venereol 1999; 12:171.
  36. Alexander AM. Maturational hyperpigmentation. In: Dermatology for Skin of Color, Kelly AP, Taylor SC (Eds), McGraw-Hill, New York 2009.
  37. Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg 2009; 35:1163.
  38. Sarkar R. Idiopathic cutaneous hyperchromia at the orbital region or periorbital hyperpigmentation. J Cutan Aesthet Surg 2012; 5:183.
  39. Goodman RM, Belcher RW. Periorbital hyperpigmentation. An overlooked genetic disorder of pigmentation. Arch Dermatol 1969; 100:169.
  40. Malakar S, Lahiri K, Banerjee U, et al. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol 2007; 73:323.
  41. Watanabe S, Nakai K, Ohnishi T. Condition known as "dark rings under the eyes" in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg 2006; 32:785.
  42. Graziosi AC, Quaresma MR, Michalany NS, Ferreira LM. Cutaneous idiopathic hyperchromia of the orbital region (CIHOR): a histopathological study. Aesthetic Plast Surg 2013; 37:434.
  43. Vavouli C, Katsambas A, Gregoriou S, et al. Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles. J Cosmet Dermatol 2013; 12:204.
  44. Ma G, Lin XX, Hu XJ, et al. Treatment of venous infraorbital dark circles using a long-pulsed 1,064-nm neodymium-doped yttrium aluminum garnet laser. Dermatol Surg 2012; 38:1277.
  45. Xu TH, Yang ZH, Li YH, et al. Treatment of infraorbital dark circles using a low-fluence Q-switched 1,064-nm laser. Dermatol Surg 2011; 37:797.
  46. Momosawa A, Kurita M, Ozaki M, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg 2008; 121:282.
  47. Youn S, Shin JI, Kim JD, et al. Correction of infraorbital dark circles using collagenase-digested fat cell grafts. Dermatol Surg 2013; 39:766.
  48. Sharad J. Dermal Fillers for the Treatment of Tear Trough Deformity: A Review of Anatomy, Treatment Techniques, and their Outcomes. J Cutan Aesthet Surg 2012; 5:229.
  49. Bernardini FP, Cetinkaya A, Devoto MH, Zambelli A. Calcium hydroxyl-apatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags. Ophthal Plast Reconstr Surg 2014; 30:34.
  50. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol 2011; 65:689.
  51. Hori Y, Kawashima M, Oohara K, Kukita A. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984; 10:961.
  52. Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol 2009; 61:88.
  53. Ee HL, Wong HC, Goh CL, Ang P. Characteristics of Hori naevus: a prospective analysis. Br J Dermatol 2006; 154:50.
  54. Ee HL, Goh CL, Khoo LS, et al. Treatment of acquired bilateral nevus of ota-like macules (Hori's nevus) with a combination of the 532 nm Q-Switched Nd:YAG laser followed by the 1,064 nm Q-switched Nd:YAG is more effective: prospective study. Dermatol Surg 2006; 32:34.
  55. Cho SB, Park SJ, Kim MJ, Bu TS. Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) using 1064-nm Q-switched Nd:YAG laser with low fluence. Int J Dermatol 2009; 48:1308.
  56. Kunachak S, Leelaudomlipi P, Sirikulchayanonta V. Q-Switched ruby laser therapy of acquired bilateral nevus of Ota-like macules. Dermatol Surg 1999; 25:938.
  57. Polnikorn N, Tanrattanakorn S, Goldberg DJ. Treatment of Hori's nevus with the Q-switched Nd:YAG laser. Dermatol Surg 2000; 26:477.
  58. Suh DH, Han KH, Chung JH. Clinical use of the Q-switched Nd:YAG laser for the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs) in Koreans. J Dermatolog Treat 2001; 12:163.
  59. Chang MW. Disorders of hyperpigmentation. In: Dermatology, 3rd ed, Jorizzo JL, Bolognia JL, Schaffer JV (Eds), Elsevier Saunders, Philadelphia 2012. Vol 1, p.1049.
  60. Callender VD, St Surin-Lord S, Davis EC, Maclin M. Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Am J Clin Dermatol 2011; 12:87.
  61. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol 2010; 3:20.
  62. rorsman H. Riehl's melanosis. Int J Dermatol 1982; 21:75.
  63. Bangert S, Levine N. Riehl's Melanosis. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing, Malden, MA 2006. p.961.
  64. Khanna N, Rasool S. Facial melanoses: Indian perspective. Indian J Dermatol Venereol Leprol 2011; 77:552.
  65. Bovenschen HJ, Seyger MM. Erythrosis pigmentosa mediofacialis: familial occurrence. Acta Derm Venereol 2009; 89:210.
  66. Juhlin L, Alkemade H. Erythrosis pigmentosa mediofacialis (Brocq) and erythromelanosis follicularis faciei et colli in the same patient. Acta Derm Venereol 1999; 79:65.
  67. Pérez-Bernal A, Muñoz-Pérez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1:261.
  68. Sardana K, Relhan V, Garg V, Khurana N. An observational analysis of erythromelanosis follicularis faciei et colli. Clin Exp Dermatol 2008; 33:333.
  69. Kim WJ, Song M, Ko HC, et al. Topical tacalcitol ointment can be a good therapeutic choice in erythromelanosis follicularis faciei et colli. J Am Acad Dermatol 2012; 67:320.
  70. Li YH, Zhu X, Chen JZ, et al. Treatment of erythromelanosis follicularis faciei et colli using a dual-wavelength laser system: a split-face treatment. Dermatol Surg 2010; 36:1344.
  71. Inamadar AC, Palit A, Sampagavi VV, et al. Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India. Int J Dermatol 2008; 47:154.
  72. Bandyopadhyay D, Ghosh SK. Mucocutaneous manifestations of Chikungunya fever. Indian J Dermatol 2010; 55:64.
  73. Riyaz N, Riyaz A, Rahima, et al. Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India. Indian J Dermatol Venereol Leprol 2010; 76:671.
  74. Kandhari R, Khunger N, Singh A. Flagellate pigmentation and exacerbation of melasma following chikungunya fever: a less frequently reported finding. Indian J Dermatol Venereol Leprol 2012; 78:774.
  75. Axéll T, Hedin CA. Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Scand J Dent Res 1982; 90:434.
  76. Nwhator SO, Winfunke-Savage K, Ayanbadejo P, Jeboda SO. Smokers' melanosis in a Nigerian population: a preliminary study. J Contemp Dent Pract 2007; 8:68.
  77. Taybos G. Oral changes associated with tobacco use. Am J Med Sci 2003; 326:179.
  78. Hedin CA, Pindborg JJ, Axéll T. Disappearance of smoker's melanosis after reducing smoking. J Oral Pathol Med 1993; 22:228.
  79. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2:213.
  80. Merola JF, Meehan S, Walters RF, Brown L. Exogenous ochronosis. Dermatol Online J 2008; 14:6.
  81. Hardwick N, Van Gelder LW, Van der Merwe CA, Van der Merwe MP. Exogenous ochronosis: an epidemiological study. Br J Dermatol 1989; 120:229.
  82. Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.
  83. Charlín R, Barcaui CB, Kac BK, et al. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol 2008; 47:19.
  84. Diven DG, Smith EB, Pupo RA, Lee M. Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser. J Dermatol Surg Oncol 1990; 16:1018.
  85. Kanechorn-Na-Ayuthaya P, Niumphradit N, Aunhachoke K, et al. Effect of combination of 1064 nm Q-switched Nd:YAG and fractional carbon dioxide lasers for treating exogenous ochronosis. J Cosmet Laser Ther 2013; 15:42.
  86. Simmons BJ, Griffith RD, Bray FN, et al. Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol 2015; 16:205.
  87. Chaptini C, Huilgol SC. Erbium-doped yttrium aluminium garnet ablative laser treatment for endogenous ochronosis. Australas J Dermatol 2015; 56:212.
  88. Tan SK. Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser. J Cosmet Laser Ther 2013; 15:274.
  89. Dedhia A, Someshwar S, Jerajani HR. Idiopathic eruptive macular pigmentation: What is it actually? Int J Dermatol 2015; 54:1462.
  90. Sanz de Galdeano C, Léauté-Labrèze C, Bioulac-Sage P, et al. Idiopathic eruptive macular pigmentation: report of five patients. Pediatr Dermatol 1996; 13:274.
  91. Chandran V, Kumarasinghe SP. Macular pigmentation of uncertain aetiology revisited: two case reports and a proposed algorithm for clinical classification. Australas J Dermatol 2017; 58:45.
  92. Verma S, Thakur BK. Idiopathic eruptive macular pigmentation with papillomatosis. Indian Dermatol Online J 2011; 2:101.
  93. Brandão Neto RA, de Carvalho JF. Diagnosis and classification of Addison's disease (autoimmune adrenalitis). Autoimmun Rev 2014; 13:408.
  94. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am 2013; 42:869.
  95. Morgan AJ, Schwartz RA. Diabetic dermopathy: A subtle sign with grave implications. J Am Acad Dermatol 2008; 58:447.
  96. Mishra SK, Gupta N, Goswami R. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 2007; 92:1693.
  97. McCullen MA, Crawford DH, Hickman PE. Screening for hemochromatosis. Clin Chim Acta 2002; 315:169.
  98. Barton JC. Hemochromatosis and iron overload: from bench to clinic. Am J Med Sci 2013; 346:403.
  99. Santos PC, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of hereditary hemochromatosis. Int J Mol Sci 2012; 13:1497.
  100. Kang S, Lerner EA, Sober AJ, Levine N. Pigmentary disorders from exogenous causes. In: Pigmentation and Pigmentary Disorders, Levine N (Ed), CRC Press, 1993. p.417.
  101. Lerner EA, Sober AJ. Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. Dermatol Clin 1988; 6:327.
  102. Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol 2004; 43:230.
  103. Torrelo A, Zaballos P, Colmenero I, et al. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol 2005; 19:422.
  104. Nelson MR, Lawrence AG, Staughton RC, Gazzard BG. Erythema dyschromicum perstans in an HIV antibody-positive man. Br J Dermatol 1992; 127:658.
  105. Lambert WC, Schwartz RA, Hamilton GB. Erythema dyschromicum perstans. Cutis 1986; 37:42.
  106. Correa MC, Memije EV, Vargas-Alarcón G, et al. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients. J Am Acad Dermatol 2007; 56:617.
  107. Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Lever's Histopathology of the Skin, Elder DE, Elenitsas R, Johnson BL, et al (Eds), Lippincott Williams & Wilkins, Philadelphia 2009. p.172.
  108. Shiohara T, Kano Y. Lichen planus and lichenoid dermatoses. In: Dermatology, 3rd ed, Jorizzo JL, Bolognia JL, Schaffer JV (Eds), Elsevier Saunders, Philadelphia 2012. Vol 1, p.183.
  109. Mahajan VK, Chauhan PS, Mehta KS, Sharma AL. Erythema Dyschromicum Perstans: Response to Topical Tacrolimus. Indian J Dermatol 2015; 60:525.
  110. Bahadir S, Cobanoglu U, Cimsit G, et al. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol 2004; 43:220.
  111. Baranda L, Torres-Alvarez B, Cortes-Franco R, et al. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Arch Dermatol 1997; 133:325.
  112. Piquero-Martín J, Pérez-Alfonzo R, Abrusci V, et al. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity. Int J Dermatol 1989; 28:198.
  113. Silverberg NB, Herz J, Wagner A, Paller AS. Erythema dyschromicum perstans in prepubertal children. Pediatr Dermatol 2003; 20:398.
  114. Rieder E, Kaplan J, Kamino H, et al. Lichen planus pigmentosus. Dermatol Online J 2013; 19:20713.
  115. Kanwar AJ, Dogra S, Handa S, et al. A study of 124 Indian patients with lichen planus pigmentosus. Clin Exp Dermatol 2003; 28:481.
  116. Dlova NC. Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link? Br J Dermatol 2013; 168:439.
  117. Pirmez R, Duque-Estrada B, Donati A, et al. Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia. Br J Dermatol 2016; 175:1387.
  118. Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol 2010; 24:535.
  119. Kim JE, Won CH, Chang S, et al. Linear lichen planus pigmentosus of the forehead treated by neodymium:yttrium-aluminum-garnet laser and topical tacrolimus. J Dermatol 2012; 39:189.
  120. Han XD, Goh CL. A case of lichen planus pigmentosus that was recalcitrant to topical treatment responding to pigment laser treatment. Dermatol Ther 2014; 27:264.
  121. Kim GH, Mikkilineni R. Lichen planus actinicus. Dermatol Online J 2007; 13:13.
  122. Dammak A, Masmoudi A, Boudaya S, et al. [Childhood actinic lichen planus (6 cases)]. Arch Pediatr 2008; 15:111.
  123. Meads SB, Kunishige J, Ramos-Caro FA, Hassanein AM. Lichen planus actinicus. Cutis 2003; 72:377.
  124. Ramírez P, Feito M, Sendagorta E, et al. Childhood actinic lichen planus: successful treatment with antimalarials. Australas J Dermatol 2012; 53:e10.
  125. Jansen T, Gambichler T, von Kobyletzki L, Altmeyer P. Lichen planus actinicus treated with acitretin and topical corticosteroids. J Eur Acad Dermatol Venereol 2002; 16:174.
  126. Gallo L, Ayala F, Ayala F. Relapsing lichen actinicus successfully treated with cyclosporin. J Eur Acad Dermatol Venereol 2008; 22:370.
  127. Santos-Juanes J, Mas-Vidal A, Coto-Segura P, et al. Pigmented actinic lichen planus successfully treated with intense pulsed light. Br J Dermatol 2010; 163:662.
  128. Tidman MJ, Wells RS, MacDonald DM. Pachyonychia congenita with cutaneous amyloidosis and hyperpigmentation--a distinct variant. J Am Acad Dermatol 1987; 16:935.
  129. Robinson MF, Furst EJ, Nunziata V, et al. Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. Henry Ford Hosp Med J 1992; 40:249.
  130. Yoshida A, Takahashi K, Tagami H, Akasaka T. Lichen amyloidosis induced on the upper back by long-term friction with a nylon towel. J Dermatol 2009; 36:56.
  131. Chang YT, Liu HN, Wong CK, et al. Detection of Epstein-Barr virus in primary cutaneous amyloidosis. Br J Dermatol 1997; 136:823.
  132. Bandhlish A, Aggarwal A, Koranne RV. A clinico-epidemiological study of macular amyloidosis from north India. Indian J Dermatol 2012; 57:269.
  133. Kumakiri M, Hashimoto K. Histogenesis of primary localized cutaneous amyloidosis: sequential change of epidermal keratinocytes to amyloid via filamentous degeneration. J Invest Dermatol 1979; 73:150.
  134. Hurabe K, Nakayama J, Hori Y. Cutaneous amyloidosis. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund J, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, Malden, MA 2006. p.924.
  135. Qiao J, Fang H, Yao H. Amyloidosis cutis dyschromica. Orphanet J Rare Dis 2012; 7:95.
  136. Castanedo-Cazares JP, Lepe V, Moncada B. Lichen amyloidosis improved by 0.1% topical tacrolimus. Dermatology 2002; 205:420.
  137. Carlesimo M, Narcisi A, Orsini D, et al. A case of lichen amyloidosus treated with acitretin. Clin Ter 2011; 162:e59.
  138. An Q, Zhang L, Zheng S, et al. Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases. Dermatol Ther 2013; 26:263.
  139. Behr FD, Levine N, Bangert J. Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine. Arch Dermatol 2001; 137:553.
  140. Grimmer J, Weiss T, Weber L, et al. Successful treatment of lichen amyloidosis with combined bath PUVA photochemotherapy and oral acitretin. Clin Exp Dermatol 2007; 32:39.
  141. Shah KR, Boland CR, Patel M, et al. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol 2013; 68:189.e1.
  142. Devulder F, Bouché O, Diebold MD, et al. [Cronkhite-Canada syndrome: a new French case]. Gastroenterol Clin Biol 1999; 23:407.
  143. Beleznay K, Humphrey S, Au S. Erythema ab igne. CMAJ 2010; 182:E228.
  144. Arnold AW, Itin PH. Laptop computer-induced erythema ab igne in a child and review of the literature. Pediatrics 2010; 126:e1227.
  145. Adams BB. Heated car seat-induced erythema ab igne. Arch Dermatol 2012; 148:265.
  146. Berk DR. Terra firma-forme dermatosis: a retrospective review of 31 patients. Pediatr Dermatol 2012; 29:297.
  147. Nordlund JJ, Ortonne JP. The normal color of human skin. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, Malden, MA 2006.
  148. Zhang R, Zhu W. Coexistence of pigmentary demarcation lines types C and E in one subject. Int J Dermatol 2011; 50:863.
  149. Kalter DC, Griffiths WA, Atherton DJ. Linear and whorled nevoid hypermelanosis. J Am Acad Dermatol 1988; 19:1037.
  150. Di Lernia V. Linear and whorled hypermelanosis. Pediatr Dermatol 2007; 24:205.
  151. Hartmann A, Hofmann UB, Hoehn H, et al. Postnatal confirmation of prenatally diagnosed trisomy 20 mosaicism in a patient with linear and whorled nevoid hypermelanosis. Pediatr Dermatol 2004; 21:636.
  152. Verghese S, Newlin A, Miller M, Burton BK. Mosaic trisomy 7 in a patient with pigmentary abnormalities. Am J Med Genet 1999; 87:371.
  153. Kubota Y, Shimura Y, Shimada S, et al. Linear and whorled nevoid hypermelanosis in a child with chromosomal mosaicism. Int J Dermatol 1992; 31:345.
  154. Betz RC, Planko L, Eigelshoven S, et al. Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease. Am J Hum Genet 2006; 78:510.
  155. Basmanav FB, Fritz G, Lestringant GG, et al. Pathogenicity of POFUT1 in Dowling-Degos disease: additional mutations and clinical overlap with reticulate acropigmentation of kitamura. J Invest Dermatol 2015; 135:615.
  156. Basmanav FB, Oprisoreanu AM, Pasternack SM, et al. Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease. Am J Hum Genet 2014; 94:135.
  157. Kim YC, Davis MD, Schanbacher CF, Su WP. Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases. J Am Acad Dermatol 1999; 40:462.
  158. Wenzel G, Petrow W, Tappe K, et al. Treatment of Dowling-Degos disease with Er:YAG-laser: results after 2.5 years. Dermatol Surg 2003; 29:1161.
  159. Yun JH, Kim JH, Choi JS, et al. Treatment of Dowling-Degos disease with fractional Er:YAG laser. J Cosmet Laser Ther 2013; 15:336.
  160. Kono M, Sugiura K, Suganuma M, et al. Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease. Hum Mol Genet 2013; 22:3524.
  161. Tang JC, Escandon J, Shiman M, Berman B. Presentation of reticulate acropigmentation of kitamura and dowling-degos disease overlap. J Clin Aesthet Dermatol 2012; 5:41.
  162. Kameyama K, Morita M, Sugaya K, et al. Treatment of reticulate acropigmentation of Kitamura with azelaic acid. An immunohistochemical and electron microscopic study. J Am Acad Dermatol 1992; 26:817.
  163. Lugassy J, McGrath JA, Itin P, et al. KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome. J Invest Dermatol 2008; 128:1517.
  164. Lugassy J, Itin P, Ishida-Yamamoto A, et al. Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14. Am J Hum Genet 2006; 79:724.
  165. Heimer WL 2nd, Brauner G, James WD. Dermatopathia pigmentosa reticularis: a report of a family demonstrating autosomal dominant inheritance. J Am Acad Dermatol 1992; 26:298.
  166. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011; 2011:480.
  167. Knight SW, Heiss NS, Vulliamy TJ, et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999; 65:50.
  168. Hayashi M, Suzuki T. Dyschromatosis symmetrica hereditaria. J Dermatol 2013; 40:336.
  169. Miyamura Y, Suzuki T, Kono M, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet 2003; 73:693.
  170. Oyama M, Shimizu H, Ohata Y, et al. Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. Br J Dermatol 1999; 140:491.
  171. Kawakami T, Otaguchi R, Kyoya M, et al. Patient with dyschromatosis symmetrica hereditaria treated with miniature punch grafting, followed by excimer light therapy. J Dermatol 2013; 40:771.
  172. Kumar S, Mahajan BB, Singh R Jr. Dyschromatosis universalis hereditaria: a rare entity. Dermatol Online J 2011; 17:6.
  173. Al Hawsawi K, Al Aboud K, Ramesh V, Al Aboud D. Dyschromatosis universalis hereditaria: report of a case and review of the literature. Pediatr Dermatol 2002; 19:523.
  174. Bukhari IA, El-Harith EA, Stuhrmann M. Dyschromatosis universalis hereditaria as an autosomal recessive disease in five members of one family. J Eur Acad Dermatol Venereol 2006; 20:628.
  175. Stuhrmann M, Hennies HC, Bukhari IA, et al. Dyschromatosis universalis hereditaria: evidence for autosomal recessive inheritance and identification of a new locus on chromosome 12q21-q23. Clin Genet 2008; 73:566.
  176. Zhang C, Li D, Zhang J, et al. Mutations in ABCB6 cause dyschromatosis universalis hereditaria. J Invest Dermatol 2013; 133:2221.
  177. Liu H, Li Y, Hung KK, et al. Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria. PLoS One 2014; 9:e87250.
  178. Rycroft RJ, Calnan CD, Wells RS. Universal dyschromatosis, small stature and high-tone deafness. Clin Exp Dermatol 1977; 2:45.
  179. Shono S, Toda K. Universal dyschromatosis associated with photosensitivity and neurosensory hearing defect. Arch Dermatol 1990; 126:1659.
  180. Helbig I, Fölster-Holst R, Brasch J, et al. Dyschromatosis ptychotropica: an unusual pigmentary disorder in a boy with epileptic encephalopathy and progressive atrophy of the central nervous system-a novel entity? Eur J Pediatr 2010; 169:495.
  181. Nogita T, Mitsuhashi Y, Takeo C, Tsuboi R. Removal of facial and labial lentigines in dyschromatosis universalis hereditaria with a Q-switched alexandrite laser. J Am Acad Dermatol 2011; 65:e61.
  182. McCarthy PM, Piehler JM, Schaff HV, et al. The significance of multiple, recurrent, and "complex" cardiac myxomas. J Thorac Cardiovasc Surg 1986; 91:389.
  183. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86:4041.
  184. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008; 3:13.
  185. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19:230.
  186. Rauen KA, Schoyer L, McCormick F, et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 2010; 152A:4.
  187. Digilio MC, Sarkozy A, de Zorzi A, et al. LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet A 2006; 140:740.
  188. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009; 61:1.
  189. Brems H, Pasmant E, Van Minkelen R, et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat 2012; 33:1538.
  190. Denayer E, Chmara M, Brems H, et al. Legius syndrome in fourteen families. Hum Mutat 2011; 32:E1985.
  191. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.
  192. Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 2012; 7 Suppl 1:S4.
  193. Pichard DC, Boyce AM, Collins MT, Cowen EW. Oral pigmentation in McCune-Albright syndrome. JAMA Dermatol 2014; 150:760.
  194. Ozawa T, Tateishi C, Shirakawa M, et al. Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser. Dermatol Surg 2011; 37:263.
  195. Halder RM, Nordlund JJ. Topical treatment of pigmentary disorders. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, Malden, MA 2006.
  196. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011; 65:699.
Topic Outline